results, potential and shareprice

I have discussed most facets of NRT but want to talk about results, further achievements and potential to be followed by a summary which discusses the share price.

Part 1. Results and marketing.

Sofar NRT has a winner in NV07-a, previously referred to. Apparently it is better than any product on the market. One exclusive International Conference to discuss this product has been held and there is another one to come.

Prof. Alan Husband is in charge of the work associated with this and will front any conferences.

Is NV07a big? Yes, it will be. A massive market awaits this product and I believe that in 2003, agreements will be signed with the largest Cosmetic companies.
No approval from the FDA is needed.

The expected royalties and milestone payments together with the $30 mill. cash in hand will pay for NRT Trials for years to come, in my opinion. (The Phenoxodiol trials are financed by "Marshall Edwards INC or MEI and NRT holds 95%).

Then we have the OTC (over the counter products). These concern the very good seller Promensil, Rimostil and Trinovin.
The coming Patents in Dec? for Promensil will shake the existing market which infringes on this Patent.

Further trials are being held particularly with Promensil, the only clinically approved drug which gives relief from Menopause symptoms.

One notices that although NRT has other promising drugs in the pipeline, NV07-a, could greatly increase the share price once Announcements re marketing are made. On its own, it could be big enough to support NRT.

Those are my opinions.

Gerry
Tomorrow: Further Achievements and Potential.